This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clorox (CLX) Down 3.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clorox (CLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clorox's Innovations on Track: Kingsford & Miller Lite Bring Beercoal
by Zacks Equity Research
CLX's Kingsford unit and Miller Lite, the original lite beer, are back with the Kingsford x Miller Lite Beercoal. The company's IGNITE strategy also bodes well.
Procter & Gamble Stock Slips 5% in a Month: Buy the Dip or Stay Wary?
by Rajani Lohia
PG faces near-term headwinds related to the market issues in Greater China, geopolitical tensions and financial impacts of currency volatility.
Clorox Q3 Earnings & Sales Miss Estimates, Margin Expands, Stock Down
by Zacks Equity Research
CLX's Q3 results show strong core fundamentals, market share stability, and gross margin expansion despite economic headwinds and shifting shopping habits.
Trading Week Starts Out on the Soft Side
by Mark Vickery
Decent ISM Services numbers couldn't turn the tide on Monday's mild selloff.
Clorox (CLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Clorox (CLX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Clorox (CLX) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of -7.64% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Warren Buffett Announces Stepping Down in 2026
by Zacks Equity Research
Warren Buffett Announces Stepping Down in 2026.
Pre-Market Futures in the Red to Start New Trading Week
by Mark Vickery
Following a storng end to last week's trading and the "surprise" announcement of Warren Buffett stepping down, pre-markets are lower the Monday.
Clorox Pre-Q3 Earnings Send Mixed Signals: Time to Accumulate Shares?
by Zacks Equity Research
CLX Q3 results are expected to reflect gains from innovations, digital transformation and pricing and cost-saving initiatives amid tough operating conditions.
ADRNY vs. CLX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADRNY vs. CLX: Which Stock Is the Better Value Option?
Unlocking Q3 Potential of Clorox (CLX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Clorox (CLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
WK Kellogg (KLG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
WK Kellogg (KLG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Clorox (CLX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How You Should Play Clorox Stock After a 12% Drop in 6 Months
by Zacks Equity Research
CLX is navigating short-term pressures while leaning on its IGNITE strategy and digital transformation to spark long-term growth and shareholder value.
How to Boost Your Portfolio with Top Consumer Staples Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Procter & Gamble's Valuation Looks Pricey: Time to Buy, Hold or Sell?
by Rajani Lohia
PG's global reach and brand strength support long-term growth, but valuation, China headwinds and macro risks warrant a cautious, hold-worthy outlook.
Why Clorox (CLX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Clorox (CLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Consumer Staples Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Colgate's Path to Sustainable Growth: Innovation & Digital Expansion
by Zacks Equity Research
CL drives long-term growth through innovation, digital expansion and sustainability while tackling market challenges with strategic investments and efficiency.
Clorox's Strategic Vision Entails Balancing Growth Amid Cost Woes
by Zacks Equity Research
CLX navigates cost challenges while driving growth through strategic investments, innovation and global expansion.
Zacks Industry Outlook The Procter & Gamble, Colgate-Palmolive, Kimberly-Clark and The Clorox
by Zacks Equity Research
The Procter & Gamble, Colgate-Palmolive, Kimberly-Clark and The Clorox have been highlighted in this Industry Outlook article.
4 Consumer Product Stocks to Keep an Eye on Despite Market Challenges
by Ansuiya Mohta
The Zacks Consumer Products - Staples industry is navigating a tough consumer environment and elevated SG&A costs. Nevertheless, PG, CL, KMB and CLX are leveraging innovations to drive growth.
PG's Brand Strength & Strategy Fuel Resilience Amid Economic Pressures
by Zacks Equity Research
Procter & Gamble's strong brands, pricing strategy and efficiency drive growth, ensuring resilience amid macroeconomic and geopolitical challenges.
Implied Volatility Surging for Clorox (CLX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Clorox (CLX) stock based on the movements in the options market lately.